Recombinant Mouse Tumor necrosis factor receptor superfamily member 6 (Fas)

What is Recombinant Mouse Tumor Necrosis Factor Receptor Superfamily Member 6 (Fas) and what is its role in normal physiology?

Recombinant Mouse Fas (also known as CD95, Apo1, or TNFRSF6) is a laboratory-synthesized version of the naturally occurring Fas protein. It is a type I transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). While primarily recognized as a death receptor that mediates apoptosis when engaged by its ligand (FasL), research has demonstrated that Fas can also convey survival and proliferation signals under specific cellular conditions .

In normal physiology, Fas plays a crucial role in regulating programmed cell death, particularly in the immune system where it helps maintain homeostasis by eliminating activated lymphocytes after an immune response. The liver has been shown to be especially susceptible to Fas-mediated cytotoxicity in mouse models .

How does the structure of Mouse Fas compare to other TNF receptor superfamily members?

Fas shares structural similarities with other TNF receptor superfamily members, particularly in its characteristic extracellular domain with cysteine-rich motifs and an intracellular death domain. While the search results don't provide specific structural details about Fas itself, comparison with Death Receptor 6 (DR6/TNFRSF21) indicates that these receptors typically contain multiple cysteine-rich motifs in their extracellular domains followed by a transmembrane segment and a cytoplasmic region containing a death domain .

The recombinant form is designed to maintain these structural features while potentially incorporating modifications that facilitate experimental use, such as tags for purification or detection.

What experimental models are best suited for studying Fas-mediated mechanisms?

Liver models are particularly well-established for studying Fas-mediated effects, as research has shown that administration of agonistic anti-Fas antibody leads to rapid and severe liver injury in wild-type mice . This makes hepatocyte cultures and mouse liver injury models excellent systems for investigating Fas-mediated apoptosis.

When selecting experimental models, researchers should consider:

• Cell-based systems: Hepatocytes, activated T cells, and certain cancer cell lines show high sensitivity to Fas-mediated apoptosis

• Genetic models: Mice with various genetic backgrounds, including TNFR1/TNFR2 knockout mice, which show resistance to Fas-mediated liver injury

• Ex vivo systems: Precision-cut liver slices or isolated primary cells that maintain tissue architecture while allowing experimental manipulation

For methodologically sound experiments, each model system should include appropriate controls as detailed in later sections of this FAQ.

How should experimental designs account for potential contradictions in Fas-mediated signaling?

Fas signaling can lead to seemingly contradictory outcomes (apoptosis versus survival/proliferation) depending on the cellular context. To account for these contradictions:

• Use multiple readouts to measure both apoptotic and non-apoptotic outcomes

• Investigate dose-dependency, as different concentrations may trigger different signaling pathways

• Consider cell type specificity by including diverse cell types

• Assess the cytokine microenvironment, as this may influence Fas signaling outcomes

• Examine temporal dynamics of signaling events

• Account for genetic background effects, as demonstrated by the dramatic differences between wild-type and TNFR knockout mice in response to Fas activation

When analyzing contradictory results, consider employing multivariate analysis methods similar to the partial least squares (PLS) analyses used in personality trait research , which can help identify complex relationships between multiple variables in your experimental data.

What are the appropriate controls for experiments using Recombinant Mouse Fas?

Robust experimental design with appropriate controls is essential:

Negative controls:

• Untreated cells or tissues

• Treatment with denatured or functionally inactive recombinant protein

• Isotype control antibodies (when using anti-Fas antibodies)

Positive controls:

• Known inducers of apoptosis

• Validated Fas-activating antibodies or recombinant FasL

Specificity controls:

• Pre-blocking with anti-Fas antibodies

• Use of Fas-deficient cells or tissues (knockout models)

• Treatment with caspase inhibitors to confirm involvement of apoptotic pathways

Genetic controls:

• Wild-type versus knockout comparisons (e.g., TNFR1/2 knockout mice show resistance to Fas-mediated effects)

• Examination of different genetic backgrounds or strains

• Analysis of specific genetic polymorphisms that may affect Fas signaling

For in vivo experiments, particularly those involving liver injury, monitoring liver enzyme levels (ALT, AST) in the serum provides quantitative measures of injury severity.

What are the best methods for detecting Fas expression and activation in mouse tissues?

Multiple complementary techniques should be employed:

For detecting Fas expression:

• Immunohistochemistry: Visualizes Fas protein in tissue sections with preserved histological context

• Flow cytometry: Enables quantitative analysis of Fas expression on individual cells

• Western blotting: Provides information about total Fas protein levels

• RT-PCR or qPCR: Measures Fas mRNA expression levels

For detecting Fas activation:

• TUNEL assay: Detects DNA fragmentation, a hallmark of apoptosis

• Caspase activity assays: Measures activation of caspases downstream of Fas signaling

• Annexin V staining: Detects phosphatidylserine externalization, an early marker of apoptosis

• Protease activation assays: Research shows that various proteases are activated following anti-Fas antibody treatment, including caspase-3, -8, and -9-like proteases, calpains, and cathepsin B

How do genetic variations in Fas affect its function and signaling capacity?

Genetic variations can significantly impact Fas function and signaling. Research on FAS polymorphisms has revealed:

• The FAS-670 GG genotype polymorphism is associated with lower FAS mRNA expression levels (P(H1) = 0.027) , suggesting that variations in regulatory regions can affect transcription and protein availability.

• Other potential effects of genetic variations include:

  • Modified protein structure affecting ligand binding

  • Altered post-translational modifications

  • Changes in subcellular localization

  • Differential interaction with adapter proteins

The following data demonstrates how genetic polymorphisms can be linked to expression levels:

Abbreviations: CI, confidence interval; P(H1), probability of the alternate hypothesis that the difference between the sample and control groups is due only to chance; ND, sample group is not different than the control group; DOWN, downregulated.

These findings highlight the importance of considering genetic background when studying Fas-mediated effects.

What is the relationship between Fas and TNF receptor signaling pathways in experimental models?

Research has revealed a critical interplay between Fas and TNF receptor signaling pathways:

• Mice lacking TNFR1 and TNFR2 (R-) survive a single dose of agonistic anti-Fas antibody that is rapidly lethal to wild-type mice (R+) .

• TNFR-deficient mice develop only mild hepatic damage compared to the severe liver injury observed in wild-type mice , suggesting that TNF receptor signaling is required for full deployment of Fas toxicity.

• The molecular mechanisms underlying this interaction involve:

  • DNA-binding activity of NF-κB is enhanced after anti-Fas antibody treatment, but much more markedly in TNFR-deficient mice than in wild-type mice

  • Bcl2 is markedly upregulated in TNFR-deficient but not in wild-type mice challenged with anti-Fas antibody

  • Differential activation of proteases of different families (caspase-3-, -8-, and -9-like, calpains, cathepsin B)

These findings indicate that treatment with anti-Fas antibody somehow activates the TNFα-TNFRs system, and this activation synergizes with Fas-mediated signals to cause fulminant liver injury . This interaction must be considered when designing and interpreting Fas-related experiments.

How can quasi-experimental designs enhance Fas research when randomized controlled trials are not feasible?

When randomization is not possible, several quasi-experimental designs can still provide valuable insights:

• Pre-post designs with non-equivalent control groups: Compare changes before and after Fas intervention between non-randomly assigned groups. This approach is particularly useful when studying naturally occurring genetic variations in Fas or its signaling partners .

• Interrupted time series (ITS): Collect multiple measurements before and after introducing Fas or its agonists to detect changes in trends and distinguish intervention effects from background fluctuations .

• Stepped wedge designs: Introduce the Fas intervention to different groups in a staggered fashion, allowing each group to serve as its own control .

To enhance validity in these designs:

• Use multiple methods to study the same phenomenon

• Verify findings across different laboratories and experimental systems

• Test findings in diverse models to ensure generalizability

• Confirm proposed mechanisms through targeted interventions

These approaches are particularly valuable when studying complex phenomena such as the interplay between Fas and TNF receptor signaling or the effects of genetic polymorphisms on Fas function .

How should dose-response relationships for Fas-mediated effects be analyzed?

Analyzing dose-response relationships for Fas-mediated effects requires:

• Non-linear modeling: Fas-mediated effects often show sigmoidal dose-response curves. Use appropriate mathematical models (e.g., four-parameter logistic models) for curve fitting.

• EC50/IC50 determination: Calculate the effective or inhibitory concentration that produces 50% of the maximal response. For related recombinant proteins, concentrations producing 50% of optimal binding response have been reported in the range of 80-400 ng/mL .

• Statistical analysis:

  • Two-way ANOVA with dose and experimental condition as factors

  • Extra sum-of-squares F test for comparing EC50 values

  • Bootstrap resampling for confidence intervals

• Multiple endpoints analysis: Measure and analyze various outcomes (e.g., caspase activation, phosphatidylserine externalization, DNA fragmentation) separately, as they may show different dose dependencies.

• Time-dependency consideration: Include time as a variable, particularly for in vivo studies where effects can develop rapidly (within hours) following antibody administration .

What statistical methods are appropriate for analyzing contradictory results in Fas-related experiments?

When faced with contradictory results:

• Multivariate analyses: Partial least squares (PLS) analysis can identify relationships between multiple variables that may explain contradictions, similar to approaches used in personality trait research .

• Bayesian methods: These can incorporate prior knowledge and update beliefs based on new evidence, providing a framework for reconciling contradictory findings.

• Subgroup analyses: Stratifying data based on relevant factors (e.g., genetic background, cell type) may reveal that contradictions are actually consistent within specific contexts.

• Probabilistic hypothesis testing: Expressing results in terms of the probability of the alternate hypothesis (P(H1)) provides more nuanced interpretation than traditional p-values .

For example, in one study, FAS-L mRNA was upregulated in patients compared to controls (P(H1) = 0.000), while there was a significant association between FAS-670 GG genotype polymorphism and lower FAS mRNA levels (P(H1) = 0.027) . These findings can be integrated using the statistical approaches mentioned above to develop a comprehensive understanding of seemingly contradictory results.

How might advanced experimental designs help resolve current contradictions in Fas research?

Advanced experimental designs offer several advantages for resolving contradictions:

• Factorial designs: These systematically test multiple factors simultaneously and identify interactions. For example, a factorial design could examine how cell type, cytokine environment, and genetic background interact to determine Fas-mediated outcomes.

• Systems biology approaches: Computational models integrating multiple datasets can identify patterns explaining seemingly contradictory results.

• Single-cell analyses: Technologies such as single-cell RNA-seq can reveal heterogeneity within cell populations that might explain contradictions observed at the population level.

• In vivo imaging: Real-time imaging of Fas-mediated processes can provide temporal and spatial information that helps resolve contradictions based on endpoint analyses.

• Interrupted time series designs: These can help distinguish the effects of Fas activation from background trends and fluctuations .

Each of these approaches provides unique insights and, when combined, can create a more complete understanding of complex Fas-mediated mechanisms.

What are the implications of TNF receptor-Fas interactions for therapeutic targeting of death receptor pathways?

The discovery that mice lacking TNFR1 and TNFR2 are resistant to Fas-mediated liver injury has significant therapeutic implications:

• Combination approaches: Targeting both Fas and TNF receptor pathways simultaneously may be more effective than targeting either pathway alone.

• Context-dependent interventions: The therapeutic strategy should consider tissue-specific interactions between these pathways.

• Biomarker development: The expression levels and activation states of both receptor systems could serve as biomarkers for predicting response to death receptor-targeted therapies.

• Safety considerations: The severe liver injury resulting from Fas activation in the presence of functional TNF receptors suggests that therapeutic agents targeting Fas must be carefully evaluated for hepatotoxicity.

• Protective strategies: Understanding how TNFR-deficient mice upregulate Bcl2 in response to Fas activation could lead to protective strategies against Fas-mediated tissue damage.

These insights highlight the need for a systems-level understanding of death receptor interactions when developing targeted therapeutics.